deltatrials
Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT05605613

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

PD-1 Antibody in Addition to Bronchial Arterial Chemoembolization in Patients With Non-Small-Cell Lung Cancer: A Randomised Controlled Trial

Sponsor: Xuhua Duan

Conditions NSCLC
Interventions BACE PD-1 Antibody
Updated 4 times since 2022 Last updated: Nov 8, 2022 Started: Oct 29, 2022 Primary completion: Nov 15, 2023 Completion: Dec 1, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05605613, this PHASE2/PHASE3 trial focuses on NSCLC and remains ongoing. Sponsored by Xuhua Duan, it has been updated 4 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2026 · 16 months · monthly snapshotRecruiting~Jan 2026 – present · 7 months · monthly snapshotUnknown

Change History

4 versions recorded

  1. Jan 2026 — Present [monthly]

    Unknown PHASE2/PHASE3

    Status: Recruiting → Unknown

  2. Sep 2024 — Jan 2026 [monthly]

    Recruiting PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Dec 2022 — Jul 2024 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Oct 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Xuhua Duan
Data source: The First Affiliated Hospital of Zhengzhou University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations